Study of GV20-0251 in Participants With Solid Tumor Malignancies

Sponsor
GV20 Therapeutics
Study ID
NCT07070518
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GV20-0251 — DRUG
    Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks

Study Details

This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Key Dates

First listed
Jul 17, 2025
Start date
Jul 11, 2025
Status verified
Dec 2025
Primary completion
Jul 16, 2027
Completion
Sep 16, 2028

Study Design

Enrollment
350 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GV20-0251

Primary Outcome Measure

Evaluate anti-tumor activities with GV20-0251 [ Time Frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until disease progression or end of study (whichever occurs first, up to 24 months) ]

Central Contacts

Find similar trials

Nationwide
Melanoma trialsLung cancer trialsOncology trialsSkin cancer trialsDermatology trialsLung oncology trialsLung disease trials

Related Studies